Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal…

Overview of attention for article published in Clinical Kidney Journal, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#11 of 2,105)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 214 X posts from 208 X users, with an upper bound of 151,650 followers.

RT @JonathanNefro: Finerenona e iSGLT2 han sido posicionados (ambos) como fármacos de primera línea en diabetes y enfermedad renal, gracias…

RT @JonathanNefro: Finerenona e iSGLT2 han sido posicionados (ambos) como fármacos de primera línea en diabetes y enfermedad renal, gracias…

RT @CKJsocial: Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes 👉a clinical practice document by E…

RT @JonathanNefro: Finerenona e iSGLT2 han sido posicionados (ambos) como fármacos de primera línea en diabetes y enfermedad renal, gracias…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 210 additional X posts.